What is LBRX's stock-based comp?

LBRX (LBRX) reported stock-based comp of $2.57M in Q1 2026.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

LBRX LBRX Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

AlkermesALKS

$36.33M+59.3%

MapLight Therapeutics, Inc. MPLT

$9.64M+4,445%

Alto NeuroscienceANRO

$2.82M+43.5%

Zevra Therapeutics, Inc.ZVRA

$3.11M-0.3%

Opko HealthOPK

$2.74M+4.5%

Other financials

Income statement

See full

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

See full

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

See full

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

See full

Market cap$874.06M+163%

Enterprise value$556.86M—

Returns & leverage

See full

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LBRX's stock-based comp?: LBRX (LBRX) reported stock-based comp of $2.57M in Q1 2026.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.